Showing results (1221-1230 of 1,676) with videos related to

Sort By:
Pageof 168
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Journal of Medicinal Chemistry|June 15, 2019
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) InhibitorsJian Lin, Wei Lu, Justin A Caravella, et al.
Circulation|September 19, 2022
Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and WalesRochelle Knight, Venexia Walker, Samantha Ip, et al.
Conservation Biology : the Journal of the Society for Conservation Biology|February 10, 2026
An experimental approach to assess the combined effects of multiple stressors on a large vertebrate speciesEnrico Pirotta, Catriona M Harris, Lori H Schwacke, et al.
Journal of Medicinal Chemistry|July 10, 2023
Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279Silvana Leit, Jeremy Greenwood, Samantha Carriero, et al.
The Medical Journal of Australia|July 13, 2026
Program Guidelines for the National Lung Cancer Screening Program: Targeted Lung Cancer Screening in High-Risk Individuals in AustraliaNicole M Rankin, Rebecca Zosel, Lisa J Whop, et al.
The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
Journal of Medicinal Chemistry|May 5, 2016
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma KinaseWei-Sheng Huang, Shuangying Liu, Dong Zou, et al.
Pageof 168